Elin S Gray

List of Publications by Year in Descending Order

107 papers	5,015 citations	38 h-index	70 g-index
120 ext. papers	5,922 ext. citations	6 avg, IF	5.25 L-index

#	Paper	IF	Citations
107	Tumour- associated autoantibodies as prognostic cancer biomarkers- a review.. *Autoimmunity Reviews*, **2022**, 21, 103041	13.6	3
106	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.. *Prostate Cancer and Prostatic Diseases*, **2022**,	6.2	2
105	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.. *Translational Lung Cancer Research*, **2022**, 11, 440-451	4.4	0
104	Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.. *Pathology Research and Practice*, **2021**, 229, 153724	3.4	0
103	Investigating primary preservice teachersSultraviolet radiation awareness and perceived ability to teach sun safety. *Health Promotion Journal of Australia*, **2021**, 32 Suppl 2, 178-184	1.7	2
102	The Epigenetic landscape of Circulating tumour cells. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188514	11.2	4
101	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. *Cancers*, **2021**, 13,	6.6	5
100	Exercise-induced myokines and their effect on prostate cancer. *Nature Reviews Urology*, **2021**, 18, 519-542	5.5	14
99	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. *Biochimica Et Biophysica Acta - General Subjects*, **2021**, 1865, 129736	4	9
98	Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review. *Integrative Cancer Therapies*, **2021**, 20, 15347354211040757	3	
97	Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. *Computational and Structural Biotechnology Journal*, **2021**, 19, 691-704	6.8	3
96	Transcript-Based Detection of Circulating Melanoma Cells. *Methods in Molecular Biology*, **2021**, 2265, 235-245	1.4	0
95	Changes in plasma hydroxyproline and plasma cell-free DNA concentrations after higher- versus lower-intensity eccentric cycling. *European Journal of Applied Physiology*, **2021**, 121, 1087-1097	3.4	4
94	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. *Methods in Molecular Biology*, **2021**, 2265, 247-263	1.4	
93	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. *British Journal of Cancer*, **2021**,	8.7	2
92	Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. *Journal of Physical Education and Sports Management*, **2021**, 7,	2.8	2
91	Myokine Expression and Tumor-suppressive Effect of Serum following 12 Weeks of Exercise in Prostate Cancer Patients on ADT. *Medicine and Science in Sports and Exercise*, **2021**,	1.2	5

90	Multi-Marker Immunomagnetic Enrichment of Circulating Melanoma Cells. *Methods in Molecular Biology*, **2021**, 2265, 213-222	1.4	2
89	Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.. *Cancers*, **2021**, 13,	6.6	1
88	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. *Scientific Reports*, **2020**, 10, 18878	4.9	11
87	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Cells*, **2020**, 9,	7.9	11
86	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. *Nature Communications*, **2020**, 11, 2408	17.4	42
85	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. *Frontiers in Oncology*, **2020**, 10, 1041	5.3	2
84	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. *British Journal of Cancer*, **2020**, 122, 1059-1067	8.7	23
83	Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. *Journal of Molecular Diagnostics*, **2020**, 22, 429-434	5.1	2
82	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. *Scientific Reports*, **2020**, 10, 6083	4.9	12
81	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. *Clinical Cancer Research*, **2020**, 26, 4064-4071	12.9	20
80	Detection of splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. *Oncotarget*, **2020**, 11, 4016-4027	3.3	1
79	Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. *Regenerative Medicine*, **2020**, 15, 2229-2247	2.5	1
78	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. *Oncologist*, **2020**, 25, e520-e527	5.7	29
77	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. *Clinical Cancer Research*, **2020**, 26, 5926-5933	12.9	21
76	Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy **2020**, 8,		9
75	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. *Cancers*, **2020**, 12,	6.6	1
74	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond Mutant Detection. *Cancers*, **2020**, 12,	6.6	5
73	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. *Cancer Letters*, **2020**, 468, 59-71	9.9	49

72	Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. *Cancers*, **2019**, 11,	6.6	11
71	A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. *Journal of Immunological Methods*, **2019**, 468, 61-66	2.5	6
70	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. *Journal of Molecular Diagnostics*, **2019**, 21, 418-426	5.1	13
69	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. *Cancers*, **2019**, 11,	6.6	4
68	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. *Oncotarget*, **2019**, 10, 113-122	3.3	13
67	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. *BMC Cancer*, **2019**, 19, 1109	4.8	7
66	A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. *Translational Vision Science and Technology*, **2019**, 8, 12	3.3	20
65	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. *Molecular Oncology*, **2019**, 13, 171-184	7.9	27
64	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. *Journal of Molecular Diagnostics*, **2018**, 20, 240-252	5.1	24
63	Melanoma circulating tumor cells: Benefits and challenges required for clinical application. *Cancer Letters*, **2018**, 424, 1-8	9.9	27
62	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. *BMC Cancer*, **2018**, 18, 726	4.8	50
61	Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. *JCO Precision Oncology*, **2018**, 2,	3.6	11
60	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. *Scientific Reports*, **2018**, 8, 18036	4.9	5
59	A diagnostic autoantibody signature for primary cutaneous melanoma. *Oncotarget*, **2018**, 9, 30539-30551	3.3	19
58	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. *Cancer Letters*, **2017**, 404, 62-69	9.9	83
57	SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. *BMC Dermatology*, **2017**, 17, 8	2.1	5
56	Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation. *BMJ Case Reports*, **2017**, 2017,	0.9	4
55	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. *Oncotarget*, **2017**, 8, 67355-67368	3.3	34

54	Sensitive droplet digital PCR method for detection of promoter mutations in cell free DNA from patients with metastatic melanoma. *Oncotarget*, **2017**, 8, 78890-78900	3.3	39
53	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. *EBioMedicine*, **2016**, 12, 196-207	8.8	28
52	Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. *BMC Dermatology*, **2016**, 16, 6	2.1	17
51	Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. *Autoimmunity Reviews*, **2016**, 15, 477-83	13.6	130
50	UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. *Biochemistry and Biophysics Reports*, **2016**, 7, 408-414	2.2	3
49	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. *Journal of Investigative Dermatology*, **2015**, 135, 2040-2048	4.3	57
48	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. *Cell Host and Microbe*, **2015**, 18, 354-62	23.4	53
47	Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. *Clinical Biochemistry*, **2015**, 48, 999-1002	3.5	82
46	Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. *Journal of Infectious Diseases*, **2015**, 211, 1461-6	7	6
45	Arterial or Venous: Where Are the Circulating Tumor Cells?. *EBioMedicine*, **2015**, 2, 1596-7	8.8	2
44	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on 47 for replication. *Retrovirology*, **2015**, 12, 54	3.6	18
43	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. *Oncotarget*, **2015**, 6, 42008-18	3.3	238
42	Lab-on-chip platform for circulating tumor cells isolation **2015**,		1
41	Circulating Tumor Cells as Biomarkers in Cancer. *Biomarkers in Disease*, **2015**, 31-51		0
40	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. *BMC Cancer*, **2014**, 14, 423	4.8	40
39	Circulating Tumor Cells as Biomarkers in Cancer **2014**, 1-17		
38	Heat stress: a risk factor for skin carcinogenesis. *Cancer Letters*, **2013**, 337, 35-40	9.9	32
37	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. *Virology Journal*, **2013**, 10, 347	6.1	12

36	Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. *Virology*, **2013**, 446, 66-76	3.6	21
35	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. *PLoS Pathogens*, **2013**, 9, e1003738	7.6	147
34	Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. *Journal of Virology*, **2013**, 87, 4882-94	6.6	55
33	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. *Frontiers in Oncology*, **2013**, 3, 54	5.3	25
32	The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. *Virology*, **2012**, 423, 175-86	3.6	42
31	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. *Virology*, **2012**, 433, 410-20	3.6	2
30	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. *Nature Medicine*, **2012**, 18, 1688-92	50.5	234
29	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. *Journal of Translational Medicine*, **2012**, 10, 192	8.5	47
28	The development of CD4 binding site antibodies during HIV-1 infection. *Journal of Virology*, **2012**, 86, 7588-95	6.6	105
27	UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. *Journal of Virology*, **2012**, 86, 4989-99	6.6	30
26	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. *Journal of Virology*, **2011**, 85, 9998-10009	6.6	342
25	Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. *Journal of Virology*, **2011**, 85, 3128-41	6.6	128
24	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. *Journal of Virology*, **2011**, 85, 11502-19	6.6	148
23	The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. *Journal of Virology*, **2011**, 85, 4828-40	6.6	348
22	Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. *Journal of Virology*, **2011**, 85, 9039-50	6.6	44
21	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. *Journal of Virology*, **2011**, 85, 7719-29	6.6	50
20	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. *PLoS ONE*, **2011**, 6, e23532	3.7	123
19	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. *Virology*, **2010**, 402, 187-96	3.6	82

18	Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. *Journal of Virology*, **2009**, 83, 8925-37	6.6	149
17	Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. *PLoS Pathogens*, **2009**, 5, e1000598	7.6	184
16	Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. *Journal of Virology*, **2009**, 83, 11265-74	6.6	84
15	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. *Virology*, **2009**, 387, 414-26	3.6	74
14	Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. *Retrovirology*, **2009**, 6, 113	3.6	6
13	P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization. *Retrovirology*, **2009**, 6,	3.6	78
12	P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape. *Retrovirology*, **2009**, 6,	3.6	78
11	Specificity of the autologous neutralizing antibody response. *Current Opinion in HIV and AIDS*, **2009**, 4, 358-63	4.2	50
10	Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. *Journal of Virology*, **2008**, 82, 11651-68	6.6	305
9	The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. *Journal of Virology*, **2008**, 82, 1860-9	6.6	132
8	4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. *Journal of Virology*, **2008**, 82, 2367-75	6.6	34
7	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. *Virology*, **2007**, 368, 172-81	3.6	42
6	N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. *Journal of Virology*, **2007**, 81, 10769-76	6.6	40
5	Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. *Journal of Virology*, **2007**, 81, 6187-96	6.6	242
4	Entry inhibition of HIV-1 subtype C isolates **2007**, 119-131		1
3	Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. *PLoS Medicine*, **2006**, 3, e255	11.6	66
2	Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. *Journal of Biological Chemistry*, **2004**, 279, 5597-603	5.4	28
1	A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. *Molecular Immunology*, **2002**, 39, 103-12	4.3	26